Artiva Biotherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and par value data)
| AS OF | ||
|---|---|---|
| SEPTEMBER 30,2024 | DECEMBER 31,2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $55,881 | $53,504 |
| Short-term investments | 90,750 | 23,467 |
| Accounts receivable (including related party amounts of $569 and $569, respectively) | 569 | 1,034 |
| Other receivables (including related party amounts of $14 and $607, respectively) | 132 | 724 |
| Prepaid expenses and other current assets | 3,233 | 1,092 |
| Total current assets | 150,565 | 79,821 |
| Restricted cash | 258 | 258 |
| Property and equipment, net | 6,857 | 8,096 |
| Operating lease right-of-use assets | 14,376 | 16,547 |
| Financing lease right-of-use asset | 276 | — |
| Long-term investments | 52,966 | — |
| Other long-term assets | 298 | 392 |
| Total assets | $225,596 | $105,114 |
| Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable (including related party amounts of $304 and $199, respectively) | $1,215 | $614 |
| Accrued expenses (including related party amounts of $1,307 and $2,161, respectively) | 8,344 | 8,017 |
| Current portion of operating lease liabilities | 3,614 | 3,596 |
| Current portion of financing lease liability | 119 | — |
| Total current liabilities | 13,292 | 12,227 |
| Operating lease liabilities, net of current portion | 11,160 | 13,316 |
| Financing lease liability, net of current portion | 75 | — |
| Simple agreements for future equity (“SAFEs”) (including related party amounts of $0 and $20,315, respectively) | — | 25,100 |
| Other non-current liabilities | 73 | 73 |
| Total liabilities | 24,600 | 50,716 |
| Commitments and contingencies (Note 11) | ||
| Series A convertible preferred stock, $0.0001 par value; zero and 16,110,463 shares authorized as of September 30, 2024 and December 31, 2023, respectively; zero and 3,673,148 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; zero and $80,552 aggregate liquidation preference at September 30, 2024 and December 31, 2023, respectively | — | 96,767 |
| Series B convertible preferred stock, $0.0001 par value; zero and 10,909,091 shares authorized as of September 30, 2024 and December 31, 2023, respectively; zero and 2,487,237 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; zero and $120,000 aggregate liquidation preference at September 30, 2024 and December 31, 2023, respectively | — | 119,646 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.0001 par value; 10,000,000 and zero shares authorized at September 30, 2024 and December 31, 2023 respectively; zero shares issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 700,000,000 and 38,998,588 shares authorized at September 30, 2024 and December 31, 2023, respectively; 24,287,144 and 809,758 shares issued and outstanding at September 30, 2024 and December 31, 2023 | 3 | — |
| Additional paid-in capital | 431,244 | 18,988 |
| Accumulated other comprehensive income | 338 | 308 |
| Accumulated deficit | (230,589) | (181,311) |
| Total stockholders’ equity (deficit) | 200,996 | (162,015) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $225,596 | $105,114 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.